NCHR Testimony on Nucala for Eosinophilic COPD

July 26, 2018. New products must provide a real and clinically meaningful benefit, not just a hope that the treatment works. Unfortunately, the clinical trial data presented today do not provide substantial evidence that mepolizumab [Nucala] provides this benefit for patients with COPD and high eosinophil counts.

Read More »

Letter to Members of Congress Opposing the “Accurate Labels Act”

July 11, 2018. We urge you to oppose this dangerous family-unfriendly legislation that: undermines the health of the American public; eliminates states’ existing ability to inform their citizens about the ingredients of products and the dangers that they may pose; and keeps Americans in the dark about the products they bring into their homes.

Read More »

NCHR Testimony at FDA on Approval of Abuse-Deterrent Opioid, Remoxy

June 26, 2018: To reduce the opioid epidemic, the FDA must hold pharmaceutical companies to a high and truthful standard. Remoxy did not meet the FDA’s standards for oral abuse, and it remains unclear whether it can be abused intravenously. The safety of the excipient is also in question. Please carefully consider the risks of putting another drug with abuse-deterrent labeling on the market that could result in misuse and abuse in the real world. We urge this Advisory Committee to vote that the benefits of this drug do not outweigh its risks.

Read More »